Form 4: Telomir Pharmaceuticals Director Receives Stock Grant
Insider Transaction (Form 4)
Matthew Pratt Whalen, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.
Summary
- Grant/award: acquired 50,000 Non-Qualified Stock Options (right to buy) on April 16, 2026; holds 50,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Matthew Pratt Whalen — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-04-16 | Grant/award | Non-Qualified Stock Options (right to buy) | 50,000 | — | — | 50,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-04-16 | Grant/award (50,000 shares) |
Keywords
insider transaction, Form 4, TELO, Telomir Pharmaceuticals, Inc., neutral, Matthew Pratt Whalen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.